CATALOGO DEI PRODOTTI DELLA RICERCA

SCAFFIDI, Luigi
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 1.856
NA - Nord America 1.758
AS - Asia 1.427
SA - Sud America 242
AF - Africa 30
OC - Oceania 20
Continente sconosciuto - Info sul continente non disponibili 3
AN - Antartide 1
Totale 5.337
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.707
RU - Federazione Russa 904
CN - Cina 523
SG - Singapore 496
GB - Regno Unito 275
BR - Brasile 212
HK - Hong Kong 167
IT - Italia 131
DE - Germania 119
SE - Svezia 110
FR - Francia 104
IE - Irlanda 91
VN - Vietnam 88
KR - Corea 39
FI - Finlandia 36
CA - Canada 29
IN - India 28
PL - Polonia 24
AU - Australia 19
ID - Indonesia 17
MX - Messico 16
TR - Turchia 15
JP - Giappone 13
AR - Argentina 11
NL - Olanda 11
AT - Austria 8
UA - Ucraina 8
BD - Bangladesh 7
IQ - Iraq 7
BE - Belgio 6
CO - Colombia 6
CL - Cile 5
DZ - Algeria 5
TG - Togo 5
AE - Emirati Arabi Uniti 4
CG - Congo 4
ES - Italia 4
LT - Lituania 4
TN - Tunisia 4
EC - Ecuador 3
EU - Europa 3
MA - Marocco 3
UZ - Uzbekistan 3
ZA - Sudafrica 3
AZ - Azerbaigian 2
BY - Bielorussia 2
CH - Svizzera 2
CR - Costa Rica 2
CZ - Repubblica Ceca 2
LV - Lettonia 2
NO - Norvegia 2
PK - Pakistan 2
RO - Romania 2
SA - Arabia Saudita 2
SY - Repubblica araba siriana 2
TW - Taiwan 2
VE - Venezuela 2
AL - Albania 1
AM - Armenia 1
AQ - Antartide 1
BA - Bosnia-Erzegovina 1
BG - Bulgaria 1
BH - Bahrain 1
CI - Costa d'Avorio 1
CY - Cipro 1
DK - Danimarca 1
DM - Dominica 1
ET - Etiopia 1
GD - Grenada 1
GE - Georgia 1
GR - Grecia 1
IR - Iran 1
JM - Giamaica 1
JO - Giordania 1
KE - Kenya 1
KH - Cambogia 1
LB - Libano 1
LY - Libia 1
MY - Malesia 1
NG - Nigeria 1
NI - Nicaragua 1
NP - Nepal 1
NZ - Nuova Zelanda 1
PE - Perù 1
PT - Portogallo 1
PY - Paraguay 1
RS - Serbia 1
SI - Slovenia 1
SM - San Marino 1
UG - Uganda 1
UY - Uruguay 1
Totale 5.337
Salva come PNG Salva come JPEG
Città #
Chandler 293
Moscow 288
Southend 229
Dallas 228
Singapore 189
Hong Kong 167
Ashburn 164
Beijing 144
Dublin 91
Woodbridge 83
Ann Arbor 48
New York 45
Los Angeles 43
Wilmington 41
Lawrence 40
Princeton 40
The Dalles 37
Jinan 34
Shenyang 34
Jacksonville 30
Ho Chi Minh City 28
Sindelfingen 26
Nanjing 25
Columbus 23
São Paulo 23
Munich 22
Verona 22
Redondo Beach 19
Warsaw 18
Buffalo 17
Tianjin 15
Hanoi 14
Falls Church 13
Nuremberg 13
Tokyo 13
Zhengzhou 13
Hebei 12
Helsinki 12
Montreal 12
Perth 12
Phoenix 12
San Francisco 12
Santa Clara 12
Taiyuan 12
Poplar 11
Changsha 10
Redmond 10
Seoul 10
Bologna 9
Chennai 9
Dong Ket 9
Guangzhou 9
Houston 9
Jakarta 9
London 9
Nanchang 9
Redwood City 9
Seattle 8
Atlanta 7
Belo Horizonte 7
Denver 7
Norwalk 7
Rio de Janeiro 7
Stockholm 7
Taizhou 7
Brussels 6
Chengdu 6
Council Bluffs 6
Haikou 6
Kent 6
Mexico City 6
Ningbo 6
Orem 6
Thái Nguyên 6
Toronto 6
Ankara 5
Brasília 5
Düsseldorf 5
Falkenstein 5
Lomé 5
Milan 5
Porto Alegre 5
Querétaro 5
Shanghai 5
Bergamo 4
Boston 4
Canoas 4
Fairfield 4
Frankfurt am Main 4
Goiânia 4
Hangzhou 4
Lappeenranta 4
New Delhi 4
Rome 4
Turku 4
Vancouver 4
Washington 4
Biên Hòa 3
Boardman 3
Brazzaville 3
Totale 3.013
Salva come PNG Salva come JPEG
Nome #
CAL2 Monoclonal Antibody Is a Rapid and Sensitive Assay for the Detection of Calreticulin Mutations in Essential Thrombocythemia and May Provide Prognostic Informations 221
BCR-ABL fusion transcript b2a2 is associated with a higher risk of non-optimal early response in CP-CML patients treated with standard dose imatinib: a study from Gruppo Triveneto LMC. 197
Anaphylactic Reactions After Discontinuation of Hymenoptera Venom Immunotherapy: A Clonal Mast Cell Disorder Should Be Suspected 182
Predictive factors of stable deep molecular response in chronic myeloid leukemia patients treated with imatinib standard dose: a study from the Gruppo Triveneto LMC. 179
Predictors of stable deep molecular response in chronic phase chronic myeloid leukemia patients treated with dasatinib or nilotinib after imatinib failure 167
Predictors for response to ruxolitinib in real-life: an observational independent study on 266 patients with myelofibrosis 167
Regulative Loop between β-catenin and Protein Tyrosine Receptor Type γ in Chronic Myeloid Leukemia 159
CAL2 monoclonal antibody is a rapid and sensitive assay for the detection of calreticulin mutations in essential thrombocythemia patients 158
Predictors for Response to Ruxolitinib in Real-Life: An Observational Independent Study on 408 Patients with Myelofibrosis 157
The serological prevalence of SARS-CoV-2 infection in patients with chronic myeloid leukemia is similar to that in the general population 149
Imatinib-treated chronic myeloid leukemia patients with discordant response between cytogenetic and molecular tests at 3 and 6 month time-points have a reduced probability of subsequent optimal response 148
Comparison of dasatinib and nilotinib as second-line therapy after imatinib failure in chronic phase chronic myeloid leukemia patients. 147
Combination of EUTOS score and 3-month BCR-ABL transcript level identifies a group of good-risk chronic myeloid leukemia patients with favorable response to frontline imatinib therapy 146
Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis 143
Real-life comparison of dasatinib and nilotinib as second-line therapy after imatinib failure for chronic phase CML 133
Efficacy and safety of ruxolitinib in intermediate-1 IPSS risk myelofibrosis patients: Results from an independent study 130
Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms 130
Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study⁎ 130
Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation 127
Arterial thrombosis in Philadelphia-negative myeloproliferative neoplasms predicts second cancer: a case-control study 125
Excellent outcomes of 2G-TKI therapy after imatinib failure in chronic phase CML patients 125
A successful treatment-free remission is achievable also by chronic myeloid leukemia patients lacking optimal requirements 124
Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart 121
SETD2 and histone H3 lysine 36 methylation deficiency in advanced systemic mastocytosis 120
Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients 116
Bosutinib in the real-life treatment of chronic myeloid leukemia patients aged $greater$65~years resistant/intolerant to previous tyrosine-kinase inhibitors 116
Prospective assessment of NGS-detectable mutations in CML patients with nonoptimal response: the NEXT-in-CML study 114
Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors in the real-life practice: Identification of risk factors and the role of prophylaxis 112
BCR::ABL1 levels at first month after TKI discontinuation predict subsequent maintenance of treatment‐free remission: A study from the “GRUPPO TRIVENETO LMC” 99
Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib 92
Second primary malignancy in myelofibrosis patients treated with ruxolitinib 87
Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome 86
Safety and efficacy of switching from branded to generic imatinib in chronic phase chronic myeloid leukemia patients treated in Italy 83
Management of Chronic Myeloid Leukemia in Advanced Phase 81
Deferasirox in the management of iron overload in patients with myelofibrosis treated with ruxolitinib: The multicentre retrospective {RUX}-{IOL} study 79
Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis 76
Favorable outcome of chronic myeloid leukemia co-expressing e13a2 and e14a2 transcripts, treated with nilotinib 75
Second cancers in MPN: Survival analysis from an international study 57
Renin angiotensin system inhibitors reduce the incidence of arterial thrombotic events in patients with hypertension and chronic myeloid leukemia treated with second- or third-generation tyrosine kinase inhibitors 57
Successful Preservation of Native BCR::ABL1 in Chronic Myeloid Leukemia Primary Leukocytes Reveals a Reduced Kinase Activity 55
Long-term mortality rate for cardiovascular disease in 656 chronic myeloid leukaemia patients treated with second- and third-generation tyrosine kinase inhibitors 55
Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study 54
Low low-density lipoprotein (LDL), cholesterol and triglycerides plasma levels are associated with reduced risk of arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life. A Campus CML study 53
Incidence of blast phase in myelofibrosis patients according to anemia severity at ruxolitinib start and during therapy 52
The new Systematic Coronary Risk Evaluation (SCORE2 and SCORE2-OP) estimates the risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib or ponatinib 50
Ropeginterferon versus Standard Therapy for Low-Risk Patients with Polycythemia Vera 50
Recurrent arterial occlusive events in patients with chronic myeloid leukemia treated with second- and third-generation tyrosine kinase inhibitors and role of secondary prevention 48
Ropeginterferon phase 2 randomized study in low-risk polycythemia vera: 5-year drug survival and efficacy outcomes 39
Refined diagnostic criteria for bone marrow mastocytosis: a proposal of the European competence network on mastocytosis 37
Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcome 22
Totale 5.430
Salva come PNG Salva come JPEG
Categoria #
all - tutte 20.656
article - articoli 16.549
book - libri 0
conference - conferenze 4.107
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 41.312
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202182 0 0 0 0 0 28 1 2 3 3 22 23
2021/2022308 31 80 16 40 10 10 6 14 11 2 14 74
2022/2023711 42 82 69 121 72 167 3 41 77 11 14 12
2023/2024398 11 36 19 52 33 32 14 18 10 41 102 30
2024/20251.078 46 57 39 187 60 39 83 76 137 67 97 190
2025/20262.014 217 188 206 542 838 23 0 0 0 0 0 0
Totale 5.430